Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$133.73
-2.7%
$132.75
$99.71
$141.23
$239.05B0.736.11 million shs9.44 million shs
Cronos Group Inc. stock logo
CRON
Cronos Group
$1.91
+1.1%
$1.93
$1.60
$2.54
$728.94M1.041.35 million shs773,288 shs
Evotec AG stock logo
EVO
Evotec
$4.22
+1.4%
$4.10
$2.84
$5.64
$1.48B1.66134,041 shs76,640 shs
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
$4.74
+0.6%
$4.62
$2.03
$6.07
$736.57M0.712.01 million shs1.33 million shs
10 Stocks Set to Soar in Summer 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Abbott Laboratories stock logo
ABT
Abbott Laboratories
-2.71%+1.04%+0.60%+2.23%+27.52%
Cronos Group Inc. stock logo
CRON
Cronos Group
+1.06%0.00%-4.50%+6.70%-17.67%
Evotec AG stock logo
EVO
Evotec
+1.44%+6.30%-1.40%+27.49%-10.21%
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
+0.64%+3.49%-1.86%-15.05%+115.45%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Abbott Laboratories stock logo
ABT
Abbott Laboratories
4.9468 of 5 stars
2.45.04.24.53.02.52.5
Cronos Group Inc. stock logo
CRON
Cronos Group
2.3851 of 5 stars
0.05.00.00.02.50.02.5
Evotec AG stock logo
EVO
Evotec
2.1381 of 5 stars
3.24.00.00.02.20.00.6
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
4.1869 of 5 stars
3.42.00.04.22.72.50.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Abbott Laboratories stock logo
ABT
Abbott Laboratories
2.76
Moderate Buy$142.616.64% Upside
Cronos Group Inc. stock logo
CRON
Cronos Group
0.00
N/AN/AN/A
Evotec AG stock logo
EVO
Evotec
2.40
Hold$5.9340.60% Upside
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
2.83
Moderate Buy$6.2531.86% Upside

Current Analyst Ratings Breakdown

Latest EVO, CRON, ABT, and XERS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/16/2025
Abbott Laboratories stock logo
ABT
Abbott Laboratories
Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold
6/16/2025
Abbott Laboratories stock logo
ABT
Abbott Laboratories
Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageMarket Perform$143.00
5/15/2025
Evotec AG stock logo
EVO
Evotec
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform
5/9/2025
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$6.00 ➝ $7.00
4/24/2025
Evotec AG stock logo
EVO
Evotec
Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeSell ➝ Hold
4/17/2025
Abbott Laboratories stock logo
ABT
Abbott Laboratories
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$133.00 ➝ $145.00
4/17/2025
Abbott Laboratories stock logo
ABT
Abbott Laboratories
Raymond James Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$132.00 ➝ $142.00
4/17/2025
Abbott Laboratories stock logo
ABT
Abbott Laboratories
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$140.00 ➝ $145.00
4/17/2025
Abbott Laboratories stock logo
ABT
Abbott Laboratories
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$117.00 ➝ $127.00
4/17/2025
Abbott Laboratories stock logo
ABT
Abbott Laboratories
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$136.00 ➝ $147.00
4/17/2025
Abbott Laboratories stock logo
ABT
Abbott Laboratories
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$158.00 ➝ $159.00
(Data available from 6/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$41.95B5.55$6.41 per share20.87$27.62 per share4.84
Cronos Group Inc. stock logo
CRON
Cronos Group
$117.61M6.26$0.00 per share4,061.72$2.90 per share0.66
Evotec AG stock logo
EVO
Evotec
$862.40M1.74N/AN/A$2.91 per share1.45
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
$203.07M3.65N/AN/A($0.20) per share-23.70
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$13.40B$7.7117.3423.342.6131.89%19.01%10.82%7/17/2025 (Estimated)
Cronos Group Inc. stock logo
CRON
Cronos Group
$41.08M$0.1314.6963.6732.1439.69%-0.07%-0.07%8/6/2025 (Estimated)
Evotec AG stock logo
EVO
Evotec
-$212.18MN/A0.00N/AN/A-26.34%-21.51%-10.54%8/13/2025 (Estimated)
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
-$54.84M-$0.30N/AN/AN/A-20.25%N/A-12.07%8/6/2025 (Estimated)

Latest EVO, CRON, ABT, and XERS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
7/17/2025Q2 2025
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$1.25N/AN/AN/A$11.01 billionN/A
5/8/2025Q1 2025
Cronos Group Inc. stock logo
CRON
Cronos Group
$0.01$0.02+$0.01$0.02$45.44 million$33.62 million
5/8/2025Q1 2025
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
-$0.07-$0.06+$0.01-$0.06$57.61 million$57.80 million
4/16/2025Q1 2025
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$1.07$1.09+$0.02$0.76$10.38 billion$10.36 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$2.361.76%N/A30.61%54 Years
Cronos Group Inc. stock logo
CRON
Cronos Group
N/AN/AN/AN/AN/A
Evotec AG stock logo
EVO
Evotec
N/AN/AN/AN/AN/A
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
N/AN/AN/AN/AN/A

Latest EVO, CRON, ABT, and XERS Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
6/13/2025
Abbott Laboratories stock logo
ABT
Abbott Laboratories
quarterly$0.591.73%7/15/20257/15/20258/15/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Abbott Laboratories stock logo
ABT
Abbott Laboratories
0.26
1.78
1.27
Cronos Group Inc. stock logo
CRON
Cronos Group
N/A
27.80
26.75
Evotec AG stock logo
EVO
Evotec
0.46
2.03
1.93
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
N/A
1.72
1.17

Institutional Ownership

CompanyInstitutional Ownership
Abbott Laboratories stock logo
ABT
Abbott Laboratories
75.18%
Cronos Group Inc. stock logo
CRON
Cronos Group
8.71%
Evotec AG stock logo
EVO
Evotec
5.81%
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
42.75%

Insider Ownership

CompanyInsider Ownership
Abbott Laboratories stock logo
ABT
Abbott Laboratories
0.46%
Cronos Group Inc. stock logo
CRON
Cronos Group
7.30%
Evotec AG stock logo
EVO
Evotec
1.00%
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
6.47%
CompanyEmployeesShares OutstandingFree FloatOptionable
Abbott Laboratories stock logo
ABT
Abbott Laboratories
114,0001.74 billion1.73 billionOptionable
Cronos Group Inc. stock logo
CRON
Cronos Group
450385.68 million357.53 millionOptionable
Evotec AG stock logo
EVO
Evotec
4,827355.11 million351.56 millionNot Optionable
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
290156.38 million146.27 millionOptionable

Recent News About These Companies

Xeris Announces Details for Analyst & Investor Day

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Abbott Laboratories stock logo

Abbott Laboratories NYSE:ABT

$133.73 -3.67 (-2.67%)
Closing price 06/26/2025 03:59 PM Eastern
Extended Trading
$134.06 +0.33 (+0.25%)
As of 04:31 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for laboratories. In addition, the company provides pediatric and adult nutritional products; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.

Cronos Group stock logo

Cronos Group NASDAQ:CRON

$1.91 +0.02 (+1.06%)
Closing price 06/26/2025 04:00 PM Eastern
Extended Trading
$1.91 0.00 (0.00%)
As of 06/26/2025 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cronos Group Inc. operates as a cannabinoid company that engages in the cultivation, production and marketing of cannabis products in Canada, Israel, and Germany. It offers dried flower, pre-rolls, oils, vaporizers, edibles, and cannabis tinctures under the Spinach, Lord Jones, and PEACE NATURALS brands. Cronos Group Inc. was founded in 2012 and is based in Toronto, Canada.

Evotec stock logo

Evotec NASDAQ:EVO

$4.22 +0.06 (+1.44%)
Closing price 06/26/2025 04:00 PM Eastern
Extended Trading
$4.22 0.00 (0.00%)
As of 04:02 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health. It has collaboration agreements with SK bioscience, JingXin, Carrick Therapeutics, Sernova, Topas Therapeutics, Exscientia, CONBA Group, Centrexion, Sanofi/NIH, Kazia Therapeutics, Bristol Myers Squibb, Topas Therapeutics, Immunitas, Exscientia, and Bayer; and Inserm, the French National Institute of Health and Medical Research, Lille University Hospital, and Inserm Transfert to identify novel therapeutic targets and diagnostic and prognostic markers in obesity and metabolic diseases, as well as collaboration with CHDI Foundation, Inc.; and a strategic partnership with Dewpoint Therapeutics to advance its portfolio targeting biomolecular condensates as a novel domain for therapeutic intervention towards the clinic, as well as research collaboration with Pfizer for metabolic and infectious diseases. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.

Xeris Biopharma stock logo

Xeris Biopharma NASDAQ:XERS

$4.74 +0.03 (+0.64%)
Closing price 06/26/2025 04:00 PM Eastern
Extended Trading
$4.76 +0.02 (+0.42%)
As of 06/26/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.